To establish the clinical relevance, we conducted analyses of IFNGR1Low SKCMs and ICB-resistant patient melanomas, which also showed expected changes of target genes regulated by mTOR and JAK1/2, indicating a similar activation of the mTOR-JAK axis in human melanomas with impaired IFN-γ signaling and ICB resistance. The gene discussed is JAK1; the disease is melanoma.